Omega-3 fatty acids: New insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid

Current Opinion in Lipidology

Volumn 24, Issue 6, 2013, Pages 467-474

  Davidson, Michael H ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Omthera Pharmaceuticals Inc   (United States)

Author keywords

docosahexaenoic acid; docosapentaenoic acid; eicosapentaenoic acid; FADS polymorphisms; omega 3 fatty acids

Indexed keywords

ACYL COENZYME A DESATURASE 1; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; FIBRIC ACID DERIVATIVE; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LONG CHAIN FATTY ACID; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; OMEGA 3 FATTY ACID ESTER; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN;

AMINO ACID BLOOD LEVEL; BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FLUSHING; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOGENESIS; LIPOLYSIS; LOW FAT DIET; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SIDE EFFECT;

ANIMALS; BIOLOGICAL AVAILABILITY; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACID DESATURASES; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; HUMANS;

EID: 84888286731     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000019     Document Type: Review

References (47)

1. Bang HO, Dyerberg J. Plasma lipids and lipoproteins in Greenlandic west coast Eskimos. Acta Med Scand 1972; 192:85-94.
2. Martinelli N, Girelli D, Malerba G, et al. FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linoleic acid are associated with inflammation and coronary artery disease. Am J Clin Nutr 2008; 88:941-949.
3. Schaeffer L, Gohlke H, Muller M, et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum Mol Genet 2006; 15:1745-1756.
4. Lemaitre RN, Tanaka T, Tang W, et al. Genetic loci associated with plasma phospholipid n-3 fatty acids: A meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet 2011; 7:E1002193.
5. Deo RC, Reich D, Tandon A, et al. Genetic differences between the determinants of lipid profile phenotypes in African and European Americans: The Jackson Heart Study. PLoS Genet 2009; 5:E1000342.
6. Martinelli N, Consoli L, Olivieri O. A 'desaturase hypothesis' for atherosclerosis: Janus-faced enzymes in v-6 and v-3 polyunsaturated fatty acid metabolism. J Nutrigenet Nutrigenomics 2009; 2:129-131.
7. Brasky TM, Darke AK, Song X, et al. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst 2013; 105:1132-1141. A recent observational study linking omega-3 fatty acids to prostate cancer, but it did not take into account the potential role of FADS polymorphisms as a more likely association for the higher incidence of prostate cancer
8. Azordegan N, Fraser V, Le K, et al. Carcinogenesis alters fatty acid profile in breast tissue. Mol Cell Biochem 2013; 374:223-232.
9. Hong MG, Karlsson R, Magnusson PK, et al. A genome-wide assessment of variability in human serum metabolism. Hum Mutat 2013; 34:515-524.
10. He C, Qu X, Wan J, et al. Inhibiting delta-6 desaturase activity suppresses tumor growth in mice. PLoS One 2012; 7:E47567. These data may provide a mechanism by which omega-3 fatty acids may reduce the development of cancer
11. Brasky TM, Kristal AR, Navarro SL, et al. Specialty supplements and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort. Nutr Cancer 2011; 63:573-582.
12. Musunuru K, Romaine SPR, Lettre G, et al. Multiethnic analysis of lipidassociated loci: The NHLBI CARe project. PLoS One 2012; 7:E36473.
13. Willer CJ, Sanna S, Jackson AU, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008; 40:161-169.
14. Simopoulos AP. Genetic variants in the metabolism of omega-6 and omega-3 fatty acids: Their role in the determination of nutritional requirements and chronic disease risk. Exp Biol Med 2010; 235:785-795.
15. Brookes KJ, Chen W, Xu X, et al. Association of fatty acid desaturase genes with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006; 60:1053-1061.
16. Ikeda I, Sasaki E, Yasunami H, et al. Digestion and lymphatic transport of eicosapentaenoic and docosahexaenoic acids given in the form of triacylglycerol, free acid and ethyl ester in rats. Biochim Biophys Acta 1995; 1259:297-304.
17. Davidson MH, Johnson J, Rooney MW, et al. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova compared to Lovaza) in a pharmacokinetic single-dose evaluation) study. J Clin Lipidol 2012; 6:573-584.
18. Small DM. The effects of glyceride structure on absorption and metabolism. Annu Rev Nutr 1991; 11:413-434.
19. Lawson LD, Hughes BG. Absorption of eicosapentaenoic acid and docosahexaenoic acid from fish oil triacylglycerols or fish oil ethyl esters co-ingested with a high-fat meal. Biochem Biophys Res Commun 1988; 156:960-963.
20. Beckermann B, Beneke M, Seitz I. Comparative bioavailability of eicosapentaenoic acid and docosahexaenoic acid from triglycerides, free fatty acids and ethyl esters in volunteers. Arzneimittelforschung 1990; 40:700-704.
21. Offman E, Marenco T, Ferber S, et al. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: The ECLIPSE II study. Vasc Health Risk Manag 2013; 9:563-573
22. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106:3143-3421.
23. Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol 2006; 98:27i-33i.
24. Kawakami A, Yoshida M. Apolipoprotein CIII links dyslipidemia with atherosclerosis. J Atheroscler Thromb 2009; 16:6-11.
25. Iizuka K, Horikawa Y. ChREBP: A glucose-activated transcription factor involved in the development of metabolic syndrome. Endocr J 2008; 55: 617-624.
26. Chen YJ, Chen CC, Li TK, et al. Docosahexaenoic acid suppresses the expression of FoxO1 and its target genes. J Nutr Biochem 2012; 23:1609-1616. DHA may improve lipolysis of VLDL by suppressing Fox01, which regulates Apo C-III
27. Sparks JD, Dong HH. FoxO1 and hepatic lipid metabolism. Curr Opin Lipidol 2009; 20:217-226.
28. Jump DB, Botolin D, Wang Y, et al. Fatty acid regulation of hepatic gene transcription. J Nutr 2005; 135:2503-2506.
29. Olivieri O, Martinelli N, Sandri M, et al. Apolipoprotein C-III, n-3 polyunsaturated fatty acids, and 'insulin-resistant' T-455C APOC3 gene polymorphism in heart disease patients: Example of gene-diet interaction. Clin Chem 2005; 51:360-367.
30. Davidson MH, Maki KC, Bays H, et al. Effects of prescription omega-3- acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statintreated subjects with hypertriglyceridemia. J Clin Lipidol 2009; 5:332-340.
31. Maki KC, Bays HE, Dicklin MR, et al. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. J Clin Lipidol 2011; 5:483-492.
32. Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000; 102:1886-1892.
33. Barzilai N, Atzmon G, Schechter C, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 2003; 290:2030-2040.
34. Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008; 322:1702-1705.
35. Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids; a systematic review and meta-analysis. Curr Atheroscler Rep 2011; 13:474-483.
36. Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review. J Clin Lipidol 2012; 6:5-18. A meta-analysis demonstrating that both EPA and DHA decrease triglycerides, but that DHA increases both LDL-C and HDL-C.
37. Maeda N, Li H, Lee D, et al. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 1994; 269:23610-23616.
38. Chan DC, Watts GF, Barrett PHR, et al. Regulatory effects of HMG CoA reductase inhibitors and fish oils on Apo B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes 2002; 51:2377-2386.
39. Buckley R, Shewring B, Turner R, et al. Circulating triacylglycerol and Apo E levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects. Br J Nutr 2004; 92:477-483.
40. Homma Y, Ohshima K, Yamaguchi H, et al. Effects of eicosapentaenoic acid on plasma lipoprotein subfractions and activities of lecithin cholesterol acyltransferase and lipid transfer protein. Atherosclerosis 1991; 91:145-153.
41. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multicenter, plAcebo-controlled, Randomized, double-blInd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011; 108:682-690.
42. Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic acid and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000; 71:1085-1094.
43. Mozaffarian D, Wu JH. (n-3) fatty acids and cardiovascular health: Are effects of EPA and DHA shared or complementary? J Nutr 2012; 142:614S-625S.
44. Degirolamo C, Kelley K, Wilson M, Rudel L. Dietary n-3 LCPUFA from fish oil but not alpha-linolenic acid-derived LCPUFA confers atheroprotection in mice. J Lipid Res 2010; 51:1897-1905.
45. Mozaffarian D, Lemaitre RN, King IB, et al. Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults. A cohort study. Ann Intern Med 2013; 158:515-525. A prospective follow-up showing that higher plasma levels of omega-3 fatty acids are associated with lower cardiovascular mortality and that EPA and DHA may lower different major adverse cardiovascular end points
46. Tanaka K, Ishikawa Y, Yokoyama M, et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: Subanalysis of the JELIS trial. Stroke 2008; 39:2052-2058.
47. Sun Q, Ma J, Campos H, et al. Blood concentrations of individual long-chain n-3 fatty acids and risk of nonfatal myocardial infarction. Am J Clin Nutr 2008; 88:216-223.